An interventional study of Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancy in Pregnancies at Increased Risk for Excessive Gestational Weight Gain, Ecological Momentary Assessment and Intervention and Continuous Glucose Monitor, sponsored by Arkansas Children's Hospital Research Institute. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-10-09.
Sponsored by Arkansas Children's Hospital Research Institute · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Obesity by Arkansas Children's Hospital Research Institute — 3 open to participants now, 5 under way, none of them phase 3. Obesity · Arkansas Children's Hospital Research Institute.
Among the 12 studies in Obesity by Arkansas Children's Hospital Research Institute, this one is one of 2 that started in 2025, is one of 9 with no phase, and was the 10th registered.
11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.
Browse Obesity studies →3 of the 12 studies in Obesity by Arkansas Children's Hospital Research Institute are open now, in 1 country. Recruiting first, the newest first:
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 12–17
Arkansas Children's Hospital Research Institute · Sites in United States
Ages 18+ · Women only
By country, each count listing its studies:
Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 2 started in 2025.
This study's planned enrollment of 16 is below the median of 67 across 9,043 interventional studies indexed under Obesity.
Median enrollment 106 across the 9 interventional studies, 82 across the 3 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Arkansas Children's Hospital Research Institute is the lead sponsor of 122 studies on the registry; 25 are open to participants now.
1 of the studies in Obesity by Arkansas Children's Hospital Research Institute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06666257Arkansas Children's Hospital Research InstituteContinuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancies - The GEM Study | 2027-07-30 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Obesity by Arkansas Children's Hospital Research Institute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This single-arm pilot study will evaluate the feasibility and acceptability of a remotely delivered behavioral lifestyle intervention, adapted from the SmartMoms framework, to promote health gestational weight gain in pregnant women with overweight and obesity. Twelve to sixteen participants will receive weekly virtual motivational interview sessions with trained health coaches, review their daily weight data, step count, and continuous glucose monitoring data, and tailored guidance on physical activity and nutrition. Educational content will be delivered electronically, with peer support provided through a closed online group. A simulated (mock) control arm will be created post hoc from existing records for preliminary comparisons; all enrolled participants will receive the intervention.
The purpose of this study is to assess the feasibility of delivering a remotely administered behavioral lifestyle intervention for pregnant women with overweight and obesity, adapted from the established SmartMoms framework, using a simulated (mock) control arm for comparison. This pilot study will enroll approximately 12-16 participants and will focus on evaluating feasibility, acceptability, and preliminary signals of impact to inform a future randomized controlled trial.
The intervention is tailored to the needs of women in Arkansas and aims to promote healthy gestational weight gain through motivational interviewing, physical activity promotion, education on dietary recommendations and self-monitoring. Participants will be encouraged to meet current pregnancy exercise guidelines (>= 30 minutes of moderate-intensity activity on most, if not all days) and to follow a balanced diet consistent with caloric intake recommendations for appropriate gestational weight gain based on individual pre-pregnancy BMI.
Each participant will be provided with an internet connected bodyweight scal, and pedometer for daily self-monitoring. These devices will automatically transmit weight and step data to the study team. Participants will also wear a continuous glucose monitor (CGM) throughout their pregnancy to track temporal glucose patterns, which will be reviewed with the study's registered dietitian (RD) and health coaches.
Intervention delivery will include weekly virtual motivational interview sessions with a trained health coach. Sessions will review weight gain trajectory, dietary intake, physical activity patterns, and CGM data, and will provide tailored behavioral strategies for meeting gestational weight gain goals. Educational materials will be delivered electronically to participants' smartphones. A closed online forum will be available for peer support, following the SmartMoms framework.
The simulated control arm will be generated post hoc by matching trial participants to publicly available datasets based on gestational age, BMI category, and other relevant covariates. This mock control will serve only as a comparator for preliminary analyses; all enrolled participants will receive the active intervention.
The intervention will begin between 16-20 weeks' gestation and continue until delivery (20-24 weeks per participant). All motivational interviewing sessions will be delivered remotely, and participants will be trained individually on safe and effective use of study tools.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The formative phase (Phase I), classified as exempt by the institutional review board will seek participation from individuals meeting the following criteria:
Clinical Trial (Phase 2)
Inclusion Criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women will engage in the remote intervention resembling efforts used by the SmartMoms intervention, but adapted to the needs of Arkansas women while also wearing unblinded CGM devices providing insights to glycemic trends in response to lifestyle factors.
Behavioral: Continuous Glucose and E-Monitoring to Support Healthy Weight Gain in Pregnancy
The intervention we are basing our adaptations on is a ecological momentary intervention, meaning it is integrated into participants daily lifestyle and schedule. Using an established framework for tracking daily body weight and physical activity, a gestational weight gain trajectory is estimated. Based on the data, recommendation prompts for exercise and diet will be discussed with participants during motivational interviewing. For the CGM piece, participants will wear unblinded CGM devices and have access to CGM linked app features that allow insights and reactivity to personal glycemic data
Feasibility data of the modified EMI: AR-GEM Study - Recruitment and Retention
Maternal recruitment and retention rates (total number of participants recruited and retained)
Time frame: continuous, from study enrollment at 16-20 weeks until study completion, an average of 6 months
Feasibility data of the modified EMI: SmartMomsAR - Acceptability
Acceptability scores from online intervention satisfaction questionnaires, 5 point Likert Scale system
Time frame: continuous, from study enrollment at 16-20 weeks until study completion, an average of 6 months
Feasibility data of the modified EMI: SmartMomsAR - Protocol Adherence
Adherence to study protocol via process measures. (Percentage of complete data points)
Time frame: continuous, from study enrollment at 16-20 weeks until study completion, an average of 6 months
Incidence of appropriate gestational weight gain per 2009 NASM guidelines.
Frequencies (percentage) of appropriate gestational weight gain incidence. Maternal weight (lbs) over time.
Time frame: data is derived through study completion, an average of 6 months.
Change in healthful lifestyle behaviors - HEI
Change scores for healthy eating index (HEI)
Time frame: data is derived through study completion, an average of 6 months.
Change in healthful lifestyle behaviors - Steps (Physical Activity)
Change scores for physical activity counts (steps) as assessed commercial accelerometer.
Time frame: data is derived through study completion, an average of 6 months.
Change in healthful lifestyle behaviors - Glycemic profile
Summary of glycemic profile data (mg/dL) as assessed by CGM.
Time frame: data is derived through study completion, an average of 6 months.
Plan to share: Yes
Supporting information: Study protocol, Statistical analysis plan, Analytic code
Time frame: Within 21 days of having IRB approval for the finalized phase II protocol (anticipated to be available 05/01/25)
Access criteria: Individual participant data (IPD) from this feasibility pilot study will be shared with qualified researchers conducting analyses that align with the study's objectives, specifically in relation to [study-specific areas of interest, e.g., behavior modification in pregnancy, glucose metabolism, etc.]. All data requests must include a detailed research proposal outlining planned analyses and the statistical methods. Proposals will be reviewed by the Principal Investigator and an independent review board for scientific validity, ethical considerations, and alignment with study objectives. A Data Sharing Agreement (DSA) must be signed prior to data release. Documents can be submitted via [email/portal], and requests will be reviewed within [timeframe]. Data will be shared via a secure, restricted-access repository.
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Jul 2027, 28 months after the start.
Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 28 months is above that.
Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 9, 2026: start Oct 2025 → Mar 2025, primary completion Apr 2026 → Jul 2027 and completion Jul 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Arkansas Children's Hospital Research Institute →